Home » Drug Information » FDA Approved Drugs » 1997
Medical Areas: Cardiology/Vascular Diseases
View By:YearCompanyConditionsTherapeutic AreasDrug Names
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Company: Faulding, Mylan Laboratories
Approval Status: Approved July 1997
Treatment Area: chronic occlusive arterial disease
Pentoxifylline is a 400 mg extended release tablet and the
generic equivalent of Trental. It is being marketed by Hoechst
Marion Roussel. Pentoxifylline extended release tablets are
indicated for the treatment of leg pain caused chronic occlusive
arterial disease of the limbs. Patient walking distance and daily
activities are limited by the disease. Both Faulding and Mylan are
now manufacturing Pentoxifylline.
In a comparison between aspirin and pentoxifylline in the
elderly, the level of pain did not change significantly with either
aspirin or pentoxifylline, but patient’s walking distance was
extended with the pentoxifylline group.
Mechanism of Action
Pentoxifylline increases red blood cell flexibility and improves